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Summary Urinary LTE4 reflects the whole body production of the cysteinyl-
leukotrienes (LTC4, LTD4 and LTE4) that are established mediators in asthma. The
influence of chronic inhaled and oral glucocorticoid treatment on urinary excretion of
leukotriene (LT) E4 was investigated in subjects with asthma. Enzyme immunoassay
analysis of LTE4 was performed in spot urine samples collected from 40 patients with
severe asthma, 25 patients with mild–moderate asthma and 20 non-asthmatic control
subjects. Urinary LTE4 was significantly higher in patients with severe asthma
ð69:775:5Þ as compared to mild–moderate asthma (45:773:3 with Po0:0004) and
control (42:572:5 with Po0:0001). Despite chronic systemic treatment with
glucocorticoids, chronically severe asthma had presented with higher levels of LTE4
compared to mild–moderate asthma and healthy controls. The findings support
previous indications that one important component in asthmatic airway inflamma-
tion, the cysteinyl-leukotriene pathway remains relatively unopposed by oral
glucocorticoids.






Asthma is a chronic inflammatory disorder of the
airways in which cysteinyl leukotrienes (CysLTs;
LTC4, LTD4, and LTE4) play a central role.
1 Leuko-
trienes are inflammatory mediators derived from
arachidonic acid by the action of 5-lipoxygenase
leading to the formation of LTA4.
2 The action of
LTC4 synthase subsequently leads to the formation
of LTC4, which is transformed into LTD4 and LTE4.
The potent biological action of the CysLTs includes
bronchoconstriction,3 induction of plasma exuda-
tion 4 as well as promotion of mucus secretion in
the airways.5 Several inflammatory cells possess
the biosynthetic capacity to produce CysLTs, and
LTE4 is the end-product of metabolism CysLTs in the
human lung.6 It is established that measurement of
the excretion of LTE4 in the urine provides an index
of CysLT production, and can be used in patients
with asthma.7–9
Glucocorticoids are the most potent and effec-
tive anti-inflammatory agents used in the treat-
ment of asthma.10 There are severe asthmatics who
require long-term treatment with systemic gluco-
corticoids to control their symptoms and these
patients are thus usually called glucocorticoid-
dependent severe asthmatics.11 We have previously
demonstrated that long-term corticotherapy in vivo
attenuated the formation of 5-lipoxygenase pro-
ducts in human polymorphonuclear leukocytes
(PMN) stimulated ex vivo but no effect was seen
after short-term in vivo or in vitro treatment.12
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The aim of the present study was to determine if
baseline urinary excretion of LTE4 was different in
severe asthma with patients treated chronically
with moderate to high doses of oral steroids. To test
this hypothesis we compared a group of patients
with severe asthma to a group of patients with




Asthma was defined according to the American
Thoracic Society criteria.13 None of the patients
suffered from afflictions that could affect urinary
LTE4 (e.g. kidney or liver function abnormalities or
other inflammatory diseases).14–16 Clinical charac-
teristic of all the subjects are presented in Table 1.
Forty non-smoking patients with severe asthma
ranging in age from 22 to 74 years were included in
the study according to methods previously de-
scribed.17 Severe asthma was determined accord-
ing to 2 years follow-up of these patients when
despite a clinical optimal management, we felt to
wean these patients from oral steroids. All these
patients were treated on a regular basis with
prednisone (mean dose7SD: 31.3723.1mg/day)
and 2000 mg of inhaled fluticasone propionate,
100 mg of salmeterol and 10mg/kg of long acting
theophylline. Four of the patients were aspirin-
intolerant as documented by history. The compli-
ance with prednisone therapy was assessed by
measuring 8 AM plasma and saliva cortisol levels
(Table 1).
Twenty-five non-smoking patients with mild–
moderate asthma ranging in age from 23 to 69 years
were also included. They were all symptomatic and
their asthma was classified as mild–moderate
according to the GINA guidelines.18 Half of them
were treated with low doses of inhaled steroids
(less than 1000 mg) (Table 1). All these patients had
no symptoms at the time of investigation.
Twenty non-smoking healthy volunteers ranging
in age from 25 to 63 years were also included in the
study. None of the healthy volunteers had ever
suffered from asthma and had no respiratory tract
infection.
Spot urine samples were collected in the morning
(between 8.30 and 10.30 pm) and a venipuncture
was performed in severe asthmatic patients for
evaluation of plasma cortisol, which was evaluated
using a competitive radioimmunoassay. Moreover,
at the same time of venipuncture, saliva was
collected and salivary cortisol was measured using
a commercial enzyme immunoassay kit. This study
was performed after informed consent and fulfilled
the criteria of the ethic committee of the Uni-
versity of Montpellier.
LTE4 measurements
Enzyme immunoassay (EIA) analysis of urinary LTE4
was performed with rabbit polyclonal antiserum
and acetylcholine esterase-linked tracer (Cayman
Chemical, Ann Arbor, MI, USA) as previously
described.19 Microtitre plates were coated with a
mouse monoclonal anti-rabbit IgG antibody. Solu-
tions of synthetic LTE4 standard, LTE4 acetylcholine
esterase tracer and LTE4 antiserum prepared in EIA
buffer were used. Several dilutions of unextracted
urine samples were added in duplicates. After
incubation overnight in darkness at room tempera-
ture, the enzyme substrate (Ellman’s reagent) was
added. The working detection limit was 8 pg/ml.
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Table 1 Clinical characteristic of subjects.
Asthmatics
Controls Mild–moderate Severe
Number 20 25 40
Age (years)n 46.0712.9 47.8 7 13.2 54.6 7 15.3
Sex 12F/8M 9F/16M 15F/25M
FEV1 (% of predicted) N.A. 82.7 7 15.9 62.3 7 22.9nn
Oral steroids dose (mg/day) No No 31.3 7 23.1
Inhaled steroids dose (mg/day) No 4567488 2000
Plasma cortisol (mg/100ml)a N.A. N.A. 4.976.9
Salivary cortisol (mg/100ml)b N.A. N.A. 0.270.4
nSignificant difference using Kruskal–Wallis test P ¼ 0:02:
nnSignificant difference using Mann–Whitney test P ¼ 0:0005:
aNormal value : 10–22mg/100ml.
bNormal value : 40.2 mg/100ml.
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Creatinine was measured by a colorimetrical alka-
line picrate method (Sigma, St. Louis, MO, USA) and
results are expressed as ng LTE4 per mmol
creatinine.
Statistical analysis
All the data are expressed as median and inter-
quartile or mean7SD. For comparison of LTE4
excretion among the three groups, a non-para-
metric Kruskal–Wallis and a post hoc Bonferroni–
Dunn test were performed. All the correlations
were analysed using the Spearman rank test. The
significance level was set at Po0:05:
Results
Clinical features
Subject characteristics are summarized in Table 1.
In severe asthma patients FEV1 was lower than in
patients with mild–moderate asthma (62.3722.9%
predicted versus 82.7715.9, with Po0:0005 using
the Mann–Whitney U test).
The plasma and saliva levels of cortisol in the
severe asthmatics were decreased as compared to
normal levels (Table 1). This supports compliance
with the prednisone therapy.
LTE4 excretion
The urinary excretion of LTE4 in the three groups is
presented in Fig. 1. Urinary LTE4 was significantly
higher in patients with severe asthma (69.775.5)
as compared to mild–moderate asthmatics
(45.773.3, P ¼ 0:0004 using Kruskal–Wallis test)
and control subjects (42.572.5, Po0:0001 using
Kruskal–Wallis test). There was no significant
difference in LTE4 levels between patients with
mild–moderate asthma and healthy controls
(45.773.3 vs. 42.572.5, NS).
Data correlations
There was an inverse correlation between the FEV1
value and the dose of oral steroids in severe asthma
(Rho¼0.593, P ¼ 0:0002), and a direct correla-
tion between the plasma and saliva cortisol values
(Rho¼ 0.714, P ¼ 0:0001).
No correlation was found between the urinary
LTE4 and any of the clinical parameters (FEV1,
steroid doses, plasma or saliva cortisol).
Discussion
Urinary levels of LTE4 were measured in patients
with mild–moderate and severe asthma and in
control subjects. We observed that the production
of CysLTs, as reflected in urinary LTE4 concentra-
tions, was significantly higher in severe asthma as
compared to mild–moderate asthma and control
subjects. There was however no difference in
urinary LTE4 levels between the mild–moderate
asthmatics and controls, which agrees well with
previous findings.20,21 The method used for the
measurements of LTE4 has been extensively vali-
dated 14 and there appears to be no diurnal
variation of LTE4 excretion,19 unless subjects have
an asthma attack. In addition, for this study all
samples were collected at the same time interval
during the morning hours. Another potential bias,
severe reduction in related function, could be
excluded because all subjects had serum creatinine
levels within the normal range. It is established
that subjects with aspirin-intolerance have in-
creased urinary LTE4.
8,20 However, only four (10%)
of the steroid-dependent asthmatic patients were
aspirin-intolerant. The LTE4 values for these sub-
jects were not the highest ones and fell within the
range of others. The higher levels remained even if
these subjects were excluded. Finally, the small






























Figure 1 Urinary leukotriene E4 (LTE4) in mild–moderate
asthmatics (n¼ 25), severe asthmatics (n¼ 40) and
control subjects (n¼ 20). The Kruskall–Wallis test gave
an overall significance difference (P o 0.0001). * P o
0.0001 and ** P ¼ 0.0004 using a post hoc Bonferroni–
Dunn test are the significant difference with the severe
asthma group.
Urinary LTE4 in severe asthma 1227
asthmatic patients and controlled asthmatics is
unlikely to influence the results.
It is of note that the severe asthmatic patients
had been treated for at least 2 years with oral and
inhaled steroids, but despite this, they still
presented recurrent threatening episodes of acute
asthma, and excreted high levels of LTE4 into the
urine. In this context, there are observations
suggesting that CysLTs indeed are important med-
iators of asthma exacerbations 9 and are well
known to amplify inflammation and bronchocon-
striction. The constant release of these mediators
may therefore contribute to the persistence of
symptoms leading to an uncontrolled asthma in this
group of patients.
Concerning the action of glucocorticoids on
inflammatory mediators, their effectiveness is
different for different cellular functions and also
relates to the duration of the treatment. In
previous studies, it has been found that, there
was no significant change in the level of eicosa-
noids, and more specifically urinary LTE4, after
short-term treatment for 6–9 days of prednisone in
14 atopic asthmatics.22 Likewise, 2 weeks treat-
ment with fluticasone propionate did not inhibit
allergen-induced urinary LTE4 excretion.
23 The
higher urinary LTE4 level in the steroid-dependent
asthmatic patients in this study is therefore a
further indication that steroids do not cause major
inhibition of the biosynthesis of CysLTs in vivo. We
cannot conclude from this cross-sectional study of
spot samples whether or not steroids may have had
some inhibitory effects on the leukotriene pathway,
as the patients with severe asthma theoretically
may have had even higher levels of LTE4 before
treatment. For example, in a recent study, it was
found that long-term systemic glucocorticoid treat-
ment did modify the biosynthesis of LTB4 produced
by stimulated blood PMNs ex vivo, whereas short-
term treatment did not have any effect.12 How-
ever, even if such an effect may be detectable also
on the CysLT pathway, its importance appears
marginal in view of the high levels of leukotriene
excretion and hence production that was found in
this investigation of patients that had been treated
with oral steroids for two years or more. The
patients’ compliance with treatment was docu-
mented by measurements of plasma and salivary
cortisol levels that in addition correlated well.
In summary, our study for the fist time demon-
strates that patients with severe asthma treated
with inhaled and oral steroids excrete higher levels
of LTE4 into the urine compared with non-asth-
matics or patients with mild–moderate asthma.
This generates the hypothesis that clinical control
of asthma may be improved in severe asthma if the
potent pro-inflammatory effects of the leuko-
trienes are opposed by treatment with anti-
leukotriene drugs. Recent studies indeed support
that anti-asthmatic effects over and above those
produced by glucocorticoids may be obtained by
addition of anti-leukotriene drugs.24–27 Further-
more, the unopposed leukotriene production in
these subjects may be one explanation of why they
still had asthma exacerbations during the otherwise
beneficial steroid treatment. CysLT are potent
bronchoconstrictors and their inhalation produces
changes in the lung perfusion-ventilation ratio that
share many characteristics of an asthma attack.28
Our findings warrant a study of the influence of long
term addition of anti-leukotriene drugs to steroid
therapy in severe asthmatic patients.
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